Nicox (NICXF) Short Interest


NICXF Nicox SA NICXF
37 GF Score
Price $0.30
GF Value $0.54
! 2 Warning Signs
View Full Analysis

What is Nicox Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NICXF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Nicox's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Short Interest distribution charts can be found below:

* The bar in red indicates where Nicox's Short Interest falls into.


NICXF
37GF Score
Nicox SA NICXF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nicox (NICXF) Overvalued in 2026?

Based on GuruFocus' analysis, Nicox stock appears to be undervalued. The current stock price of $0.30 is trading 44.4% below its estimated GF Value™ of $0.54.

Key valuation signals for NICXF:

  • Short Interest:
  • GF Value™: $0.54 vs. price of $0.30 (44.4% below fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the NICXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nicox Business Description

Address Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
37GF Score

Get the complete analysis for NICXF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.54
GF Value